secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001171843-24-002569
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing
---------------------------------------------------------------------

- Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.
- Cash $22.1M at March 31, 2024; plus $30.6M from May 6 financing; projected cash into Q4 2025.
- Soquelitinib Phase 1/1b PTCL: 39% ORR (5 CRs, 4 PRs) in 23 evaluable patients; disease control 61%.
- Phase 3 registrational trial for soquelitinib in PTCL planned to start Q3 2024.
- Ciforadenant Phase 1b/2 in RCC met predefined efficacy threshold; enrollment continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/0001171843-24-002569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/f8k_050624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer